The Rebound Effect of the COVID-19 Pandemic on Clinically Significant Prostate Cancer Diagnosis
Background and aim: The effect of the COVID-19 pandemic on delayed screening and consequent diagnosis of prostate cancer (PCa) is yet to be defined. This study aimed to evaluate the impact of the COVID-19 pandemic on PCa diagnosis by comparing the number of prostate biopsies performed and observing...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/15/6/3100 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849341953078984704 |
|---|---|
| author | Antonio Fanelli Ugo Giovanni Falagario Marco Finati Francesco Guzzi Antonella Ninivaggi Luca Montrone Angelo Cormio Oscar Selvaggio Pasquale Annese Gian Maria Busetto Carlo Bettocchi Francesca Sanguedolce Luigi Cormio Giuseppe Carrieri |
| author_facet | Antonio Fanelli Ugo Giovanni Falagario Marco Finati Francesco Guzzi Antonella Ninivaggi Luca Montrone Angelo Cormio Oscar Selvaggio Pasquale Annese Gian Maria Busetto Carlo Bettocchi Francesca Sanguedolce Luigi Cormio Giuseppe Carrieri |
| author_sort | Antonio Fanelli |
| collection | DOAJ |
| description | Background and aim: The effect of the COVID-19 pandemic on delayed screening and consequent diagnosis of prostate cancer (PCa) is yet to be defined. This study aimed to evaluate the impact of the COVID-19 pandemic on PCa diagnosis by comparing the number of prostate biopsies performed and observing the PCa detection rate during pre-COVID, COVID and post-COVID periods. Materials and Methods: A prospectively maintained database was queried to identify patients who received prostate biopsy between January 2018 and December 2022. The cohort was stratified into pre-COVID, COVID and post-COVID periods based on Italian government regulations. The primary study outcomes were the number of biopsies performed and the detection rate of clinically significant PCa (csPCa) in each period. Changes in the median number of biopsies were evaluated using the Kruskal–Wallis test, whereas changes in csPCa were evaluated using the chi-square test. The loess function depicted changes in the number of prostate biopsies and the csPCa detection rate across the study period. Results: Overall, 2502 patients were included; their median age was 68 (62–74) years. The median number of biopsies performed in the pre-COVID, COVID and post-COVID period was 46 (43–56), 39 (27–43) and 46 (40–58), respectively (<i>p</i> = 0.02). The most significant decrease in the number of biopsies performed was observed during the peak of the pandemic, from March to May 2020. The detection rate of csPCa in the three periods was 37%, 34% and 39%, respectively (<i>p</i> = 0.01). The loess function demonstrated a rebound effect on the number of biopsies performed and consequent csPCa diagnosed starting from November 2020, while the same effect was not observed for non-cs PCa. Conclusion: The COVID-19 pandemic caused a significant decrease in the number of prostate biopsies performed and csPCa diagnosed. We demonstrated a rebound effect on csPCa diagnosis after the pandemic. Future studies with longer follow-ups are needed to address the effects of the observed grade migration on the burden of PCa treatment and oncological outcomes. |
| format | Article |
| id | doaj-art-fbb7f086c94e4e9b8932212bd174a8f6 |
| institution | Kabale University |
| issn | 2076-3417 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Applied Sciences |
| spelling | doaj-art-fbb7f086c94e4e9b8932212bd174a8f62025-08-20T03:43:31ZengMDPI AGApplied Sciences2076-34172025-03-01156310010.3390/app15063100The Rebound Effect of the COVID-19 Pandemic on Clinically Significant Prostate Cancer DiagnosisAntonio Fanelli0Ugo Giovanni Falagario1Marco Finati2Francesco Guzzi3Antonella Ninivaggi4Luca Montrone5Angelo Cormio6Oscar Selvaggio7Pasquale Annese8Gian Maria Busetto9Carlo Bettocchi10Francesca Sanguedolce11Luigi Cormio12Giuseppe Carrieri13Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyDepartment of Urology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Università Politecnica Delle Marche, Via Conca 71, 60126 Ancona, ItalyDepartment of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyPathology Unit, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, ItalyBackground and aim: The effect of the COVID-19 pandemic on delayed screening and consequent diagnosis of prostate cancer (PCa) is yet to be defined. This study aimed to evaluate the impact of the COVID-19 pandemic on PCa diagnosis by comparing the number of prostate biopsies performed and observing the PCa detection rate during pre-COVID, COVID and post-COVID periods. Materials and Methods: A prospectively maintained database was queried to identify patients who received prostate biopsy between January 2018 and December 2022. The cohort was stratified into pre-COVID, COVID and post-COVID periods based on Italian government regulations. The primary study outcomes were the number of biopsies performed and the detection rate of clinically significant PCa (csPCa) in each period. Changes in the median number of biopsies were evaluated using the Kruskal–Wallis test, whereas changes in csPCa were evaluated using the chi-square test. The loess function depicted changes in the number of prostate biopsies and the csPCa detection rate across the study period. Results: Overall, 2502 patients were included; their median age was 68 (62–74) years. The median number of biopsies performed in the pre-COVID, COVID and post-COVID period was 46 (43–56), 39 (27–43) and 46 (40–58), respectively (<i>p</i> = 0.02). The most significant decrease in the number of biopsies performed was observed during the peak of the pandemic, from March to May 2020. The detection rate of csPCa in the three periods was 37%, 34% and 39%, respectively (<i>p</i> = 0.01). The loess function demonstrated a rebound effect on the number of biopsies performed and consequent csPCa diagnosed starting from November 2020, while the same effect was not observed for non-cs PCa. Conclusion: The COVID-19 pandemic caused a significant decrease in the number of prostate biopsies performed and csPCa diagnosed. We demonstrated a rebound effect on csPCa diagnosis after the pandemic. Future studies with longer follow-ups are needed to address the effects of the observed grade migration on the burden of PCa treatment and oncological outcomes.https://www.mdpi.com/2076-3417/15/6/3100prostatic neoplasmsCOVID-19pandemicprostate biopsy |
| spellingShingle | Antonio Fanelli Ugo Giovanni Falagario Marco Finati Francesco Guzzi Antonella Ninivaggi Luca Montrone Angelo Cormio Oscar Selvaggio Pasquale Annese Gian Maria Busetto Carlo Bettocchi Francesca Sanguedolce Luigi Cormio Giuseppe Carrieri The Rebound Effect of the COVID-19 Pandemic on Clinically Significant Prostate Cancer Diagnosis Applied Sciences prostatic neoplasms COVID-19 pandemic prostate biopsy |
| title | The Rebound Effect of the COVID-19 Pandemic on Clinically Significant Prostate Cancer Diagnosis |
| title_full | The Rebound Effect of the COVID-19 Pandemic on Clinically Significant Prostate Cancer Diagnosis |
| title_fullStr | The Rebound Effect of the COVID-19 Pandemic on Clinically Significant Prostate Cancer Diagnosis |
| title_full_unstemmed | The Rebound Effect of the COVID-19 Pandemic on Clinically Significant Prostate Cancer Diagnosis |
| title_short | The Rebound Effect of the COVID-19 Pandemic on Clinically Significant Prostate Cancer Diagnosis |
| title_sort | rebound effect of the covid 19 pandemic on clinically significant prostate cancer diagnosis |
| topic | prostatic neoplasms COVID-19 pandemic prostate biopsy |
| url | https://www.mdpi.com/2076-3417/15/6/3100 |
| work_keys_str_mv | AT antoniofanelli thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT ugogiovannifalagario thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT marcofinati thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT francescoguzzi thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT antonellaninivaggi thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT lucamontrone thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT angelocormio thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT oscarselvaggio thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT pasqualeannese thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT gianmariabusetto thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT carlobettocchi thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT francescasanguedolce thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT luigicormio thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT giuseppecarrieri thereboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT antoniofanelli reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT ugogiovannifalagario reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT marcofinati reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT francescoguzzi reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT antonellaninivaggi reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT lucamontrone reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT angelocormio reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT oscarselvaggio reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT pasqualeannese reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT gianmariabusetto reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT carlobettocchi reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT francescasanguedolce reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT luigicormio reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis AT giuseppecarrieri reboundeffectofthecovid19pandemiconclinicallysignificantprostatecancerdiagnosis |